What We're Reading: Page 393
Industry reads hand-picked by our editors
Mar 18, 2015
-
FiercePharma Marketing
Mango Health launching Rx adherence app for Apple Watch
-
Irish Times
AstraZeneca COPD blockbuster candidate shines in trial
-
Xconomy
Retrophin nabs new drug, priority review voucher
-
The Japan News
Doc admits to falsifying Diovan data
-
Pharma Times
Australian pharma lobbies for better cancer drug approval process
Mar 17, 2015
-
Reuters
Study says pricey Gilead hep C drugs are cost-effective—but what does that mean?
-
FierceBiotech
Glaxo, J&J back $100M Alzheimer's R&D project
-
Reuters
Esperion cholesterol med bests statins in trial
-
Wall Street Journal
Obesity drugs like Saxenda a hard sell to patients, docs
-
Reuters
WHO: Superbug TB strains 'ravaging' Europe
Mar 16, 2015
-
Pharma Times
FDA expands use of Actavis bipolar drug to children
-
FierceBiotech
Cidara jumps into the IPO queue
-
FiercePharma Asia
China drug approval backlog swells
-
Pharmaceutical Business Review
Baxter hemophilia drug comes through in phase III
Mar 13, 2015
Mar 12, 2015
-
Bloomberg
23andMe to expand from genetic testing to new drug development
-
The Street
Acadia CEO to retire as Parkinson's drug is delayed again
-
FiercePharma
Teva probably won't buy Mylan—but should it?
-
Reuters
CVS: Biosimilars could cut prices in half
-
Medical Marketing & Media
Open Payments glitches inhibit pharma, device maker submissions
Mar 11, 2015
-
Wall Street Journal
Rx spending soared 12% last year, driven largely by hep C meds
-
Bloomberg
A post-plastics Bayer wants to net $27B per year in healthcare sales
-
The Guardian
For AstraZeneca CEO, fending off Pfizer takeover worth 5% pay bump
-
Reuters
Merck's Keytruda first approval under UK early access program
-
CBC
License to deceive: CBC gets Health Canada to endorse sham drug in investigation
Mar 10, 2015
-
Economic Times
India set to mandate side effect reporting to regulators
-
RAPS Regulatory Focus
FDA maps out generic approvals for 38 drugs, including Kalydeco
-
Bloomberg
How much will scientists use Apple's ResearchKit?
-
FiercePharma
Opdivo's survival benefit may have led to its rapid lung cancer approval
-
WSJ Pharmalot
A German agency's recommendation for determining drug cost-effectiveness
Previous
